LifeLoc Technologies Inc (LCTC)

[Energy Manager]

Rapid Point-of-Care Serological Tests

Sandia is developing a panel of immunoassays enabling detection of viral antigens (Ags) and anti-SARS-CoV-2 antibodies (Abs) produced by the host in response to infection. These immunoassays will be implemented Sandia’s portable SpinDx platform, which also offers rapid detection without need for sample preparation. A newer version of SpinDx adds the capability to detect nucleic acid markers using a LAMP assay. Simultaneous detection of viral RNA, combined with the detection of host response to infection via immunoassays, will be a powerful way to diagnose COVID-19 at all stages of disease. Moreover, this combination of assay types would enable us to both positively identify SARS-CoV-2 and rule out influenza or other coronaviruses.